Patient Health, Innovation and the Protections Needed

Protecting Patient Health and Innovation

09.27.13 | By Scott LaGanga

Millions of patients around the world depend on innovative medicines to help them live long, healthy lives. Every time I travel to a different country, I am reminded of this fact. Just last week in Tokyo, PhRMA EVP for Advocacy Chip Davis specifically addressed how the innovative new medicines our member companies develop have enhanced the country’s health care system. At a joint symposium with the Japan Medical Association (JMA), he emphasized that new treatments have contributed to significant reductions in death from many diseases and provide significant value to Japan’s health care system. In short, they offer new hope and improved quality of life to millions.

Equally important is ensuring the safety of medicines for those who rely on them. The world is rapidly evolving, and with the growth of online pharmacies around the globe, no one knows what the future will bring. As a result, it is increasingly important to make the medical community in the country aware of the global problem posed by counterfeit medicines, and highlight some of the potential risks associated with purchasing any medicine online.

In my role as Executive Director of the Partnership for Safe Medicines in the United States, I quickly learned that education is the key to addressing this borderless issue. There is much greater cooperation as governments see how fake drugs affect their citizens, and working to educate the medical community before the problem starts is a step in the right direction. It’s critical that consumers, physicians, industry leaders and government agencies tasked with ensuring the safety of patients work together to achieve this shared goal.

Chip and I were both honored to speak before the JMA about these important issues, and we look forward to additional opportunities to discuss the importance of innovative medicines to patients and why protecting against counterfeits is essential. 


Hide Comments

More On PhRMA — powered by PhRMApedia


Cost in Context